Alzheimer's DiseaseNCT06871839
The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
An observational study of Alzheimer's Disease and Lecanemab, run by Cuibai Wei，Clinical Professor at 1 site in China.
Trial summary
Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Alzheimer's Disease, Lecanemab, Functional Magnetic Resonance Imaging
- What is being tested?
- Lecanemab treatment group and Conventional anti-dementia treatment group
- Type of treatment
- Injection or infusion
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 10 Mar 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We will recruit 120 early Alzheimer's disease (AD) patients from 13 hospitals, including Xuanwu Hospital of Capital Medical University. Among them, 60 cases will be in the Lecanemab treatment group, and 60 cases in the conventional treatment group.
Who may be able to join
- Age between 50 and 90 years.
- Male or female patients.
- Patients with MCI and mild AD.
- MMSE score ≥20, CDR overall score of 0.5 or 1.
- Amyloid-positive confirmed by Amyloid-PET or CSF.
- Have a reliable caregiver to accompany the patient during study visits and supervise the use of study medication during the trial.
- Agree to participate in the study and sign the informed consent form.
Who cannot join
- Patients with cognitive impairment due to reasons other than AD.
- A history of transient ischemic attack (TIA), stroke, cerebral hemorrhage, or seizure within the 12 months prior to screening.
- A score of >17 on the Hamilton Depression Scale at screening, or any suicidal behavior within 6 months prior to screening, at screening, or at the baseline visit, as well as any psychiatric diagnosis or symptoms that interfere with the study procedure (such as hallucinations, anxiety disorder, or paranoia).
- Patients with a bleeding disorder or receiving anticoagulant therapy, as well as any with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine, and cardiovascular system diseases that affect this study.
- A hypersensitivity reaction to ranucimab or any other ingredient in the injection solution, or to any monoclonal antibody treatment.
- Contraindications to MRI scanning, including those with a pacemaker/defibrillator or ferromagnetic metal implants (except for skull and cardiac devices approved as safe for MRI scanning).
Show all 10Show fewer
- A known or suspected history of drug or alcohol abuse or dependence within the 2 years prior to screening.
- Participation in a clinical study involving any therapeutic monoclonal antibody or novel compounds for the treatment of AD within the 6 months prior to screening, unless it can be proven that the subject was in the placebo treatment group.
- Planning to undergo surgery requiring general anesthesia during the study period.
- A positive pregnancy test result, lactation, or pregnancy in females at screening or baseline.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Capital Medical University Xuanwu Hospital
Beijing
Cui bai Wei, Ph.D, 83198319, weicb@xwhosp.org
About this study
Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.
Read the detailed description
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, impairment of daily living activities, and various behavioral and psychiatric symptoms. The most widely accepted hypothesis regarding the pathogenesis of AD is the amyloid cascade hypothesis. This hypothesis posits that the abnormal deposition of neurotoxic beta-amyloid (Aβ) is a key factor in the onset of AD. In the past two decades, anti-Aβ monoclonal antibodies aimed at reducing cerebral Aβ plaques have increasingly attracted attention in the field of AD drug development.
The humanized monoclonal antibody CAb (Lecanemab) highly targets soluble and insoluble A β[1,2] to reduce pathogenic A β plaques and prevent their formation in the brain of AD patients. Large global phase III clinical trials, including China, show that Lecanemab can slow the rate of cognitive decline in mild cognitive impairment (MCI) and mild AD within 18 months of treatment compared with placebo. However, the intrinsic mechanism by which Lecanemab delays disease progression by clearing pathogenic A β is not well understood. Previous studies have suggested that Lecanemab may have a role in improving synaptic plasticity. An animal experiment showed that the A β antibody can reverse the long-term enhanced (LTP) synaptic function defects caused by soluble A β oligomers and improve synaptic plasticity [4]. Synaptic plasticity is closely related to cognitive function. It refers to the ability to establish new connections between neurons or existing connections in the brain, which is manifested by changes in ultrastructure and functional changes of synapses, such as [5] of neurotransmitter level, neuroexcitability, electrical activity or changes in the number of postsynaptic receptors. It was shown that soluble A β oligomers are able to strongly inhibit synaptic plasticity in the normal rodent hippocampus, damage synaptic architecture, and ultimately lead to impaired cognitive [6]. Based on this, the scientific hypothesis is proposed that "Lecanemab may effectively reduce A β toxicity and protect synaptic function defects in AD brain". However, further clinical studies on the mechanism of Lecanemab on synaptic plasticity.
The purpose of this study is to prospectively evaluate the impact of continuous use of luncanemab infusion therapy on brain neural networks and synaptic plasticity in early Alzheimer's disease (AD) patients, and to explore the underlying molecular pathological mechanisms. According to the inclusion and exclusion criteria, eligible subjects are included in the screening visit period. During the screening visit, informed consent is signed, and demographic assessments are completed, along with the collection of past medical history, medication history, physical examination, and laboratory tests. Baseline neuropsychological scales, resting-state fMRI, three-dimensional structural MRI, Amyloid-PET, and blood and cerebrospinal fluid sample data are also collected. Patients are divided into a luncanemab treatment group and a conventional treatment group based on whether they receive luncanemab, and are followed up for data collection over a period of 12 months. This includes four neuropsychological assessments at 3 months, 6 months, 9 months, and 12 months of follow-up; collection of neuropsychological, resting-state fMRI, three-dimensional structural MRI, Amyloid-PET, and blood samples at baseline and at the 12-month follow-up, in accordance with patient wishes for cerebrospinal fluid sample collection; and two resting-state fMRI, three-dimensional structural MRI assessments, and blood sample collection at 6 months and 12 months of follow-up.
- Being tested
- Lecanemab treatment group, Conventional anti-dementia treatment group
- Keywords
- Alzheimer's disease, Lecanemab, functional magnetic resonance imaging
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lecanemab treatment groupDrug
Lecanemab treatment group: Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.
All subjects in the Lecanemab treatment group receive Lecanemab infusion therapy at a frequency of once every two weeks for a continuous period of 12 months.
Conventional anti-dementia treatment groupDrug
Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
| Study group | Role | What they receive |
|---|---|---|
| Lecanemab treatment group | Early-stage Alzheimer's disease patients are given Lecanemab infusion treatment in conjunction with conventional anti-dementia drug therapy. Receives: Drug: Lecanemab treatment group | |
| Conventional anti-dementia treatment | Early-stage Alzheimer's disease (AD) patients commonly take cholinesterase inhibitors such as donepezil for treatment. Receives: Drug: Conventional anti-dementia treatment group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resting-state fMRI brain network metrics (Independent Component Analysis)
The Lecanemab treatment group and the conventional treatment group's longitudinal changes in Independent Component Analysis (ICA) indicators after 12 months of treatment compared to baseline. ICA is a statistical technique used for extracting mutually independent signals from multivariate data, capable of measuring levels of functional connectivity within and between networks.
Measured: 2 years
Secondary outcomes (19)
Other resting-state fMRI brain network indicators: functional connectivity (FC)
Functional Connectivity (FC) is an important concept in neuroscience, primarily used to describe and analyze the interactions between different brain regions. FC is defined by measuring the similarity between brain signals from two regions.
Measured: 2 years
Other resting-state fMRI brain network indicators: Granger Causality Analysis (GCA)
Granger Causality Analysis: Granger causality analysis is a statistical method used to analyze the causal relationships between variables.
Measured: 2 years
Other resting-state fMRI brain network indicators: Spectral Dynamic Causal Model (spDCM)
Spectral Dynamic Causal Model (spDCM): A method for investigating the directed interactions between brain regions, also known as effective connectivity.
Measured: 2 years
Rate of change in global cognition as measured by Clinical Dementia Rating (CDR)
Assess statistically significant difference in score between Lecanemab treatment group and conventional anti-dementia treatment using the neuropsychological scales CDR. CDR, a multidimensional scale for dementia severity, which scored 0-3, with higher scores indicating worse functioning.
Measured: 2 years
Rate of change in the severity of cognitive impairment as assessed by Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-cog)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using the neuropsychological scales ADAS-cog. ADAS-cog scores range from 0-70, with higher scores indicating better global cognitive function.
Measured: 2 years
Rate of change in global cognition as measured by Mini-Mental State Examination (MMSE)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using the neuropsychological scales MMSE. MMSE scores range from 0-30, with higher scores representing better cognitive function.
Measured: 2 years
Rate of change in global cognition as measured by Montreal Cognitive Assessment (MoCA)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using the neuropsychological scales MoCA. MoCA scores range from 0-30, with higher scores representing better cognitive function.
Measured: 2 years
Alzheimer's Disease Composite Score (ADCOMS)
ADCOMS is a weighted linear combination of selected items from three commonly used scales; it consists of 12 scoring items, with scores ranging from 0 to 1.97, where higher composite scores indicate a greater severity of the disease.
Measured: 2 years
The Integrated Alzheimer's Disease Rating Scale (iADRS)
iADRS combines two separate scales, namely ADAS-Cog14 (scoring range from 0 to 90) and ADCS-iADL (the second part of ADCS-ADL, scoring range from 0 to 56). The total score range for iADRS is from 0 to 146, with lower scores indicating poorer performance.
Measured: 2 years
Five Levels Five-Dimensional Health Scale (EQ-5D-5L)
The EQ-5D includes a brief descriptive system questionnaire and a visual analogue scale (EQ VAS).
The descriptive system covers 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is divided into 5 different levels to define varying degrees of difficulty: 1 = no problems; 2 = slight problems; 3 = moderate problems; 4 = severe problems; 5 = extreme problems/unable to perform. By combining the levels of each dimension, a unique health state for the subject is defined.
Measured: 2 years
Alzheimer's Disease Quality of Life Scale (QOL-AD)
The Alzheimer's Disease Quality of Life Assessment Scale (QOL-AD), also known as the Quality of Life Assessment Scale for Senile Dementia, can evaluate multiple dimensions, including behavioral abilities, physiological functions, psychological states, interpersonal relationships, etc. The total score is the sum of the scores of 13 questions.
Measured: 2 years
Rate of change in activities of daily living as assessed by Alzheimer's Disease Cooperative Study-Activity of Daily Living (ADCS-ADL)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using the neuropsychological scales like ADCS-ADL. ADCS-ADL scores range from 0-54, with higher scores indicating better completion ability.
Measured: 2 years
Rate of change in psychobehavioral symptoms as assessed by Neuropsychiatric Inventory (NPI)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using the neuropsychological scales like NPI. Patient assessment grading scores range from 0-144 in NPI, and caregivers distress grading scores range from 0-60, with 0 representing the best.
Measured: 2 years
Hamilton Anxiety Scale (HAMA)
Hamilton Anxiety Scale: Primarily used to assess the severity of anxiety symptoms in patients with neurosis and other disorders. The total score can be used to evaluate the severity of anxiety symptoms in patients with anxiety and depressive disorders and to assess the effects of various medications and psychological interventions. According to the data provided by the Chinese Scale Collaboration Group: a total score of ≥29 may indicate severe anxiety; ≥21 definitely indicates significant anxiety; ≥14 definitely indicates anxiety; over 7 may indicate anxiety; if less than 7, there are no anxiety symptoms.
Measured: 2 years
Hamilton Depression Rating Scale (HAMD)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using Hamilton Depression Rating Scale (HAMD):It is the most widely used scale in the clinical assessment of depressive states. The HAMD uses a 5-point rating scale for most items: (0) None, (1) Mild, (2) Moderate, (3) Severe, (4) Very Severe. A few items are rated on a 3-point scale: (0) None, (1) Mild-Moderate, (2) Severe.
Result Analysis: <7 points are considered normal; 7-17 points are suspicious for depression; 18-24 points indicate mild or moderate depression; >24 points indicate severe depression.
Measured: 2 years
Zarit Caregiver Burden Interview Scale (ZBI)
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using Zarit Caregiver Burden Interview Scale (ZBI). The score range is from 0 to 88 points, with the total score being the sum of the scores for 22 questions. The score range is from 0 to 88 points, with the total score being the sum of the scores for 22 questions.
Measured: 2 years
Blood AD molecular pathology and synaptic structural protein content indicators
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using Plasma AD biomarkers (Aβ42, Aβ42/Aβ40, T-tau, P-tau181, P-tau231, P-tau217, NFL levels) and serum SV2A indicator concentration.
Measured: 2 years
Cerebrospinal Fluid Synaptic Function Protein Content Assessment Indicator
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using Cerebrospinal fluid synaptic function protein content indicator (Neurotransmitter levels: Concentrations of neurotransmitters such as glutamate, acetylcholine, norepinephrine, epinephrine, dopamine, and serotonin; Neurotrophic factors: Concentration of Brain-derived Neurotrophic Factor (BDNF); Cerebrospinal fluid synaptic markers: Presynaptic Growth-associated protein 43 (GAP-43), Synaptic body-related protein 25 (SNAP25), and postsynaptic Neuronal Granulin (NRGN) markers.)
Measured: 2 years
Neuroimaging biomarkers: Aβ-PET centiloid values
Assess statistically significant difference in score between Lecanemab treatment group and Conventional anti-dementia treatment using Aβ-PET centiloid values。 This is an indicator used to measure the level of amyloid deposition.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start10 Mar 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cuibai Wei，Clinical Professor
- Sponsor type
- University, hospital or other
- Collaborators
- Eisai (China) Pharmaceutical Co., Jinan Hospital, Xuanwu Hospital, Capital Medical University, RenJi Hospital, First Hospital of China Medical University, Nanjing Brain Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of University of Science and Technology of China, The First Hospital of Chongqing Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, West China Hospital, The First Hospital of Jilin University
- Responsible party
- Sponsor-investigator, Cuibai Wei，Clinical Professor, Xuanwu Hospital, Beijing
- Investigators
- Cui bai Wei, Principal investigator, Xuan Wu Hospital of Capital Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06871839
- Sponsor's protocol ID
- KS2024354
- Status last verified
- Mar 2025
- First submitted
- 7 Mar 2025
- Last updated
- 22 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT06871839
- Acronym / sponsor ID
- KS2024354
- Keywords
- Alzheimer's disease, Lecanemab, functional magnetic resonance imaging
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Cuibai Wei，Clinical ProfessorUniversity, hospital or other
- Collaborators
- Eisai (China) Pharmaceutical Co., Jinan Hospital, Xuanwu Hospital, Capital Medical University, RenJi Hospital, First Hospital of China Medical University, Nanjing Brain Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of University of Science and Technology of China, The First Hospital of Chongqing Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, West China Hospital, The First Hospital of Jilin University
- Study start
- 10 Mar 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.
Detailed description
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, impairment of daily living activities, and various behavioral and psychiatric symptoms. The most widely accepted hypothesis regarding the pathogenesis of AD is the amyloid cascade hypothesis. This hypothesis posits that the abnormal deposition of neurotoxic beta-amyloid (Aβ) is a key factor in the onset of AD. In the past two decades, anti-Aβ monoclonal antibodies aimed at reducing cerebral Aβ plaques have increasingly attracted attention in the field of AD drug development.
The humanized monoclonal antibody CAb (Lecanemab) highly targets soluble and insoluble A β[1,2] to reduce pathogenic A β plaques and prevent their formation in the brain of AD patients. Large global phase III clinical trials, including China, show that Lecanemab can slow the rate of cognitive decline in mild cognitive impairment (MCI) and mild AD within 18 months of treatment compared with placebo. However, the intrinsic mechanism by which Lecanemab delays disease progression by clearing pathogenic A β is not well understood. Previous studies have suggested that Lecanemab may have a role in improving synaptic plasticity. An animal experiment showed that the A β antibody can reverse the long-term enhanced (LTP) synaptic function defects caused by soluble A β oligomers and improve synaptic plasticity [4]. Synaptic plasticity is closely related to cognitive function. It refers to the ability to establish new connections between neurons or existing connections in the brain, which is manifested by changes in ultrastructure and functional changes of synapses, such as [5] of neurotransmitter level, neuroexcitability, electrical activity or changes in the number of postsynaptic receptors. It was shown that soluble A β oligomers are able to strongly inhibit synaptic plasticity in the normal rodent hippocampus, damage synaptic architecture, and ultimately lead to impaired cognitive [6]. Based on this, the scientific hypothesis is proposed that "Lecanemab may effectively reduce A β toxicity and protect synaptic function defects in AD brain". However, further clinical studies on the mechanism of Lecanemab on synaptic plasticity.
The purpose of this study is to prospectively evaluate the impact of continuous use of luncanemab infusion therapy on brain neural networks and synaptic plasticity in early Alzheimer's disease (AD) patients, and to explore the underlying molecular pathological mechanisms. According to the inclusion and exclusion criteria, eligible subjects are included in the screening visit period. During the screening visit, informed consent is signed, and demographic assessments are completed, along with the collection of past medical history, medication history, physical examination, and laboratory tests. Baseline neuropsychological scales, resting-state fMRI, three-dimensional structural MRI, Amyloid-PET, and blood and cerebrospinal fluid sample data are also collected. Patients are divided into a luncanemab treatment group and a conventional treatment group based on whether they receive luncanemab, and are followed up for data collection over a period of 12 months. This includes four neuropsychological assessments at 3 months, 6 months, 9 months, and 12 months of follow-up; collection of neuropsychological, resting-state fMRI, three-dimensional structural MRI, Amyloid-PET, and blood samples at baseline and at the 12-month follow-up, in accordance with patient wishes for cerebrospinal fluid sample collection; and two resting-state fMRI, three-dimensional structural MRI assessments, and blood sample collection at 6 months and 12 months of follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lecanemab treatment group | – | Drug: Lecanemab treatment groupEarly-stage Alzheimer's disease patients are given Lecanemab infusion treatment in conjunction with conventional anti-dementia drug therapy. |
| Conventional anti-dementia treatment | – | Drug: Conventional anti-dementia treatment groupEarly-stage Alzheimer's disease (AD) patients commonly take cholinesterase inhibitors such as donepezil for treatment. |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We will recruit 120 early Alzheimer's disease (AD) patients from 13 hospitals, including Xuanwu Hospital of Capital Medical University. Among them, 60 cases will be in the Lecanemab treatment group, and 60 cases in the conventional treatment group.
Key inclusion criteria (7 listed)
- Age between 50 and 90 years.
- Male or female patients.
- Patients with MCI and mild AD.
- MMSE score ≥20, CDR overall score of 0.5 or 1.
- Amyloid-positive confirmed by Amyloid-PET or CSF.
Key exclusion criteria (10 listed)
- Patients with cognitive impairment due to reasons other than AD.
- A history of transient ischemic attack (TIA), stroke, cerebral hemorrhage, or seizure within the 12 months prior to screening.
- A score of >17 on the Hamilton Depression Scale at screening, or any suicidal behavior within 6 months prior to screening, at screening, or at the baseline visit, as well as any psychiatric diagnosis or symptoms that interfere with the study procedure (such as hallucinations, anxiety disorder, or paranoia).
- Patients with a bleeding disorder or receiving anticoagulant therapy, as well as any with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine, and cardiovascular system diseases that affect this study.
- A hypersensitivity reaction to ranucimab or any other ingredient in the injection solution, or to any monoclonal antibody treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lecanemab treatment groupLecanemab treatment group: Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg. All subjects in the Lecanemab treatment group receive Lecanemab infusion therapy at a frequency of once every two weeks for a continuous period of 12 months. | Drug | Lecanemab treatment group |
| Conventional anti-dementia treatment groupConventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment. | Drug | Conventional anti-dementia treatment |
Primary outcome
Resting-state fMRI brain network metrics (Independent Component Analysis)
Time frame: 2 years
The Lecanemab treatment group and the conventional treatment group's longitudinal changes in Independent Component Analysis (ICA) indicators after 12 months of treatment compared to baseline. ICA is a statistical technique used for extracting mutually independent signals from multivariate data, capable of measuring levels of functional connectivity within and between networks.
19 secondary outcomes
Other resting-state fMRI brain network indicators: functional connectivity (FC)
Time frame: 2 years
Other resting-state fMRI brain network indicators: Granger Causality Analysis (GCA)
Time frame: 2 years
Other resting-state fMRI brain network indicators: Spectral Dynamic Causal Model (spDCM)
Time frame: 2 years
Rate of change in global cognition as measured by Clinical Dementia Rating (CDR)
Time frame: 2 years
Rate of change in the severity of cognitive impairment as assessed by Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-cog)
Time frame: 2 years
Rate of change in global cognition as measured by Mini-Mental State Examination (MMSE)
Time frame: 2 years
Rate of change in global cognition as measured by Montreal Cognitive Assessment (MoCA)
Time frame: 2 years
Alzheimer's Disease Composite Score (ADCOMS)
Time frame: 2 years
The Integrated Alzheimer's Disease Rating Scale (iADRS)
Time frame: 2 years
Five Levels Five-Dimensional Health Scale (EQ-5D-5L)
Time frame: 2 years
Alzheimer's Disease Quality of Life Scale (QOL-AD)
Time frame: 2 years
Rate of change in activities of daily living as assessed by Alzheimer's Disease Cooperative Study-Activity of Daily Living (ADCS-ADL)
Time frame: 2 years
Rate of change in psychobehavioral symptoms as assessed by Neuropsychiatric Inventory (NPI)
Time frame: 2 years
Hamilton Anxiety Scale (HAMA)
Time frame: 2 years
Hamilton Depression Rating Scale (HAMD)
Time frame: 2 years
Zarit Caregiver Burden Interview Scale (ZBI)
Time frame: 2 years
Blood AD molecular pathology and synaptic structural protein content indicators
Time frame: 2 years
Cerebrospinal Fluid Synaptic Function Protein Content Assessment Indicator
Time frame: 2 years
Neuroimaging biomarkers: Aβ-PET centiloid values
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
Related trials for Alzheimer's Disease
RecruitingObservational study
Speech and Language Interventions for Italian People With PPA
Primary Progressive Aphasia(PPA)
Active, not recruitingPhase 1/2
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Alzheimer's Disease (AD)
Not yet recruiting
Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease
Alzheimer&Amp;#39;s Disease-related Dementia, Alzheimer Disease
RecruitingPhase 1
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Alzheimer Disease, Alzheimer Disease (AD)
RecruitingObservational study
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Alzheimer's Disease (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cui bai Wei principal investigator
Xuan Wu Hospital of Capital Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer's Disease and Lecanemab, run by Cuibai Wei，Clinical Professor at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cui bai Wei (83198319, weicb@xwhosp.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resting-state fMRI brain network metrics (Independent Component Analysis) (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.